JP2011251985A5 - - Google Patents

Download PDF

Info

Publication number
JP2011251985A5
JP2011251985A5 JP2011157930A JP2011157930A JP2011251985A5 JP 2011251985 A5 JP2011251985 A5 JP 2011251985A5 JP 2011157930 A JP2011157930 A JP 2011157930A JP 2011157930 A JP2011157930 A JP 2011157930A JP 2011251985 A5 JP2011251985 A5 JP 2011251985A5
Authority
JP
Japan
Prior art keywords
hydrate
pharmaceutically acceptable
acceptable salt
hydroxamic acid
batch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011157930A
Other languages
English (en)
Japanese (ja)
Other versions
JP5308486B2 (ja
JP2011251985A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011251985A publication Critical patent/JP2011251985A/ja
Publication of JP2011251985A5 publication Critical patent/JP2011251985A5/ja
Application granted granted Critical
Publication of JP5308486B2 publication Critical patent/JP5308486B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011157930A 2005-05-20 2011-07-19 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法 Active JP5308486B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US68287505P 2005-05-20 2005-05-20
US60/682,875 2005-05-20
US69312805P 2005-06-23 2005-06-23
US60/693,128 2005-06-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007540436A Division JP5264174B2 (ja) 2005-05-20 2006-05-16 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Publications (3)

Publication Number Publication Date
JP2011251985A JP2011251985A (ja) 2011-12-15
JP2011251985A5 true JP2011251985A5 (enExample) 2012-10-04
JP5308486B2 JP5308486B2 (ja) 2013-10-09

Family

ID=37452585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007540436A Active JP5264174B2 (ja) 2005-05-20 2006-05-16 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法
JP2011157930A Active JP5308486B2 (ja) 2005-05-20 2011-07-19 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007540436A Active JP5264174B2 (ja) 2005-05-20 2006-05-16 スベロイルアニリドヒドロキサム酸の製剤及びこれを作製するための方法

Country Status (20)

Country Link
US (4) US8093295B2 (enExample)
EP (2) EP1853245A2 (enExample)
JP (2) JP5264174B2 (enExample)
KR (2) KR100993135B1 (enExample)
AR (1) AR055953A1 (enExample)
AU (3) AU2006249440C1 (enExample)
BR (1) BRPI0605893A (enExample)
CA (1) CA2580367C (enExample)
CR (1) CR8912A (enExample)
DO (1) DOP2006000113A (enExample)
EC (1) ECSP077263A (enExample)
IL (1) IL181070A0 (enExample)
MA (1) MA28804B1 (enExample)
MX (1) MX2007002047A (enExample)
MY (1) MY144613A (enExample)
NI (1) NI200700031A (enExample)
NZ (2) NZ594669A (enExample)
PE (1) PE20061390A1 (enExample)
TW (2) TWI365068B (enExample)
WO (2) WO2006127319A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2740559C (en) 2008-10-15 2016-02-16 Generics [Uk] Limited Improved process
WO2010061220A2 (en) * 2008-11-26 2010-06-03 Generics [Uk] Limited Novel processes and pure polymorphs
CA2744448A1 (en) * 2008-11-26 2010-06-03 Vinayak Gore Polymorphs
US20110313044A1 (en) * 2010-06-18 2011-12-22 Urquima S.A. Polymorphs of Suberoylanilide Hydroxamic Acid
EP3484470A4 (en) 2016-07-13 2020-02-26 Technion Research & Development Foundation Limited INHIBITORS OF HISTONE DEACETYLASE 4 CYTOPLASMIC COMPLEX FOR THE TREATMENT OR PREVENTION OF VASCULAR OR VALVULAR CALCIFICATION
CN107362148B (zh) * 2017-07-27 2020-04-21 东曜药业有限公司 一种治疗肿瘤的药物组合物及其制备方法和应用
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS61176523A (ja) * 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
US5055608A (en) * 1988-11-14 1991-10-08 Sloan-Kettering Institute For Cancer Research Novel potent inducers of thermal differentiation and method of use thereof
US5608108A (en) * 1988-11-14 1997-03-04 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5175191A (en) * 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
USRE38506E1 (en) * 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
JP3170069B2 (ja) * 1992-10-06 2001-05-28 日水製薬株式会社 徐放性顆粒剤
US6043389A (en) * 1997-03-11 2000-03-28 Mor Research Applications, Ltd. Hydroxy and ether-containing oxyalkylene esters and uses thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6231880B1 (en) * 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
CZ20011342A3 (cs) 1998-10-13 2001-09-12 Fujisawa Pharmaceutical Co., Ltd. Cyklické tetrapeptidy
CA2366408A1 (en) 1999-05-03 2000-11-30 Methylgene, Inc. Inhibition of histone deacetylase
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
AU6932700A (en) * 1999-09-08 2001-04-10 Sloan-Kettering Institute For Cancer Research Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
KR20020070285A (ko) 1999-11-23 2002-09-05 메틸진, 인크. 히스톤 디아세틸라제의 억제제
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
WO2002015921A2 (en) 2000-08-18 2002-02-28 The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド (e)−n−ヒドロキシ−3−(3−スルファモイル−フェニル)アクリルアミド化合物及びその治療用途
WO2002055017A2 (en) 2000-11-21 2002-07-18 Wake Forest University Method of treating autoimmune diseases
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US7199227B2 (en) * 2001-06-14 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding human histone deacetylase HDAC9c
JP4638148B2 (ja) * 2001-10-16 2011-02-23 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 神経変性疾患および脳の癌の処置
US20040132643A1 (en) * 2002-01-09 2004-07-08 Fojo Antonio Tito Histone deacelylase inhibitors in diagnosis and treatment of thyroid neoplasms
US20030235588A1 (en) * 2002-02-15 2003-12-25 Richon Victoria M. Method of treating TRX mediated diseases
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
CN1720034A (zh) * 2002-03-04 2006-01-11 艾顿药物公司 诱导末期分化的方法
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7148257B2 (en) * 2002-03-04 2006-12-12 Merck Hdac Research, Llc Methods of treating mesothelioma with suberoylanilide hydroxamic acid
US20070060614A1 (en) * 2002-03-04 2007-03-15 Bacopoulos Nicholas G Methods of treating cancer with hdac inhibitors
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
DE10218106A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelwirkstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
WO2004046104A2 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1613592A4 (en) * 2003-04-01 2008-03-12 Sloan Kettering Inst Cancer HYDROXAMIC ACID COMPOUNDS AND METHODS OF USE THEREOF
KR100924737B1 (ko) * 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Hdac 억제제를 이용한 암의 치료 방법
TWI365068B (en) * 2005-05-20 2012-06-01 Merck Sharp & Dohme Formulations of suberoylanilide hydroxamic acid and methods for producing same
CA2617623A1 (en) 2005-08-18 2007-02-22 Victoria M. Richon Combination methods of saha and targretin for treating cancer
JP2009514879A (ja) 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド Saha、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法
CN101300015A (zh) * 2005-11-04 2008-11-05 默克公司 使用n-辛二酰苯胺异羟肟酸和厄洛替尼治疗癌症的方法
EP1947936A4 (en) * 2005-11-04 2010-02-10 Merck & Co Inc METHOD FOR THE USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF CANCER

Similar Documents

Publication Publication Date Title
JP2011251985A5 (enExample)
WO2013132457A3 (en) Nanocrystalline solid dispersion compositions and process of preparation thereof
JP2014515013A5 (enExample)
JP2012502885A5 (enExample)
JP2013032389A5 (enExample)
JP2015145426A5 (enExample)
JP2013527475A5 (enExample)
JP2012067110A5 (enExample)
JP2012255026A5 (enExample)
JP2014500861A5 (enExample)
JP2015525757A5 (enExample)
JP2014167010A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2013007118A5 (enExample)
JP2014097964A5 (enExample)
TN2012000435A1 (en) Agomelatine hydrochloride hydrate and preparation thereof
JP2014511374A5 (enExample)
WO2012146980A3 (en) Preparation of fingolimod and its salts
JP2017505809A5 (enExample)
CR8912A (es) Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas
JP2012051888A5 (enExample)
JP2015512948A5 (enExample)
JP2015510935A5 (enExample)
JP2011251959A5 (enExample)
JP2012097380A5 (enExample)